Stafine-cort: Main Uses and Support

Stafine-cort is a topical agent used in the management of skin conditions where both inflammation and bacterial presence are relevant factors. It may be used to provide supportive care for common inflammatory dermatoses, including types of eczema such as atopic and discoid eczema, as well as contact dermatitis and sebaceous dermatitis. It is also used to help manage psoriasis and chronic lichen simplex.

The therapeutic application of Stafine-cort is generally confined to conditions that respond favorably to the combination of its active ingredients, which may help to alleviate symptoms associated with the skin's inflammatory response while also addressing susceptible bacterial involvement. This agent may be considered when a healthcare professional determines that both an anti-inflammatory and an antibacterial effect are suitable for the patient's condition.

Always consult a healthcare professional for guidance on its appropriate use.

---

Quick Facts: Therapeutic Domains

• Support for Inflammatory Dermatoses: May assist in the management of conditions like atopic, discoid, and stasis eczema.
• Relief for Skin Irritations: Used for supportive care of contact dermatitis and sebaceous dermatitis.
• Other Uses: Employed in the care regimen for psoriasis and chronic lichen simplex.

Who Can and Cannot Use Stafine-cort? — Official Regulatory Information

The eligibility for Stafine-cort (Fusidic Acid and Betamethasone combination) is strictly defined by regulatory documents, which establish absolute prohibitions and conditional requirements.

Eligibility Scope	Official Regulatory Status
Allowed Populations	Adults and older adults are permitted. Children six years of age and older may use the medicine, but require careful supervision due to the greater risk of systemic absorption.
Absolute Contraindications	Use is prohibited for patients with known hypersensitivity to any component and in infants under one year of age. It is also contraindicated for skin conditions such as Rosacea, Perioral Dermatitis, and infections caused by viruses (e.g., Herpes), fungi, Tuberculosis, or Syphilis.
Conditional Eligibility	Pregnancy: Should not be used unless clearly necessary due to potential risks from the Betamethasone component. Lactation: Use is allowed, but the medicine must not be applied to the breast to prevent infant ingestion. Use near the eyes must be avoided due to the risk of glaucoma or cataracts.

---

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by establishing clear absolute contraindications based on the patient's existing infectious diseases or specific inflammatory skin conditions. Eligibility is further constrained by age limits—prohibiting use in infants—and by conditional use statements for special populations like pregnant or breastfeeding women, which mandate specific precautions to mitigate potential risks.

Interaction Map: Interactions with other medicines and products — official regulatory information for Stafine-cort

Interaction Scope

Category	Officially Documented Information (Based on Regulatory Labels)
Medicinal product categories with documented interactions	CYP3A4 Inhibitors and CYP3A4 Inducers (theoretical risk related to the Betamethasone component's systemic metabolism).
Specific interacting medicines (if explicitly listed)	None are explicitly listed as clinically significant interacting medicines in the interaction section due to the product's topical route.
Mechanistic basis of interactions (only if stated in label)	Metabolic Interaction via Cytochrome P450 (CYP) enzymes, specifically the theoretical alteration of Betamethasone clearance if significant systemic absorption were to occur.
Timing-based interaction rules (if applicable)	None documented. No mandatory administration separation windows are specified.
Population-specific interaction notes (if applicable)	None documented within the dedicated interaction section.
Interaction-related restrictions	None documented as formal interaction-related restrictions (e.g., prohibited co-administration due to interaction risk).

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Interactions with systemically administered medicinal products are officially classified as minimal.
Regulatory basis (EMA / FDA / etc.)	The basis is the topical route of administration, resulting in negligible systemic exposure.
Interaction-context constraints (as defined in official documents)	The constraint is the absence of specific data: "No interaction studies have been performed."

---

Resulting Interaction Structure

Official Interaction Statements:

• No interaction studies have been performed for the Stafine-cort topical combination product.
• Interactions with systemically administered medicinal products are officially considered minimal due to the negligible systemic absorption of both active ingredients after topical application.
• The Betamethasone component is systemically metabolized by CYP enzymes; co-administration with strong CYP Inducers or Inhibitors could theoretically alter its clearance if the drug were absorbed significantly.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction structure primarily by the minimal risk inherent to its topical administration, classifying systemic medicinal product interactions as clinically minimal. This minimal risk assessment is supported by the formal regulatory statement that no dedicated interaction studies have been conducted. The profile is constrained to a high-level theoretical caution regarding strong CYP enzyme-modifying agents, a standard consideration reserved for scenarios of potential increased systemic exposure.

How Stafine-cort Works

Stafine-cort acts via a dual pharmacodynamic mechanism, combining an antibiotic and a corticosteroid to modulate two distinct physiological domains: the bacterial translational pathway and the host's glucocorticoid receptor system.

Inhibition of Bacterial Protein Production

The antibiotic component (Fusidic acid) selectively targets the elongation factor G (EF-G) on the bacterial ribosome. This interaction interferes with the translocation step of the ribosomal machinery during protein synthesis. This mechanistic interference limits the functional capacity of the bacterial ribosome to synthesize essential proteins, resulting in the cessation of bacterial protein production.

Genomic Modulation of Inflammation

The corticosteroid component (Hydrocortisone) engages the intracellular glucocorticoid receptors (GRs) within host cells. The activated GR-drug complex translocates to the cell nucleus, where it functions as a transcription factor, modulating the transcription of specific genes. This action alters the expression of genes encoding for pro-inflammatory mediators (such as cytokines) and anti-inflammatory proteins, which ultimately modulates the localized physiological response.

Stafine-cort, a fixed-dose combination product containing Fusidic Acid and Betamethasone, is strictly formulated for cutaneous use (topical application) only. Established methods and durations of administration are utilized to ensure appropriate use of the potent components.

Official Administration Protocol

Feature	Instruction Detail
Route of Administration	For cutaneous (topical) use only.
Frequency	Typically applied twice daily to the affected skin area.
Dose Amount	Apply a small quantity (a thin film). Dosage can be conceptually measured using the Fingertip Unit (FTU) standard.
Duration Limit	A single treatment course should not normally exceed 2 weeks (14 days).
Age Group	Indicated for use in adults and children over 1 year of age.

The dosing schedule involves the external application of a thin layer of the cream or ointment to the affected area. This is a fixed, short-term daily regimen, intended for a duration not exceeding two weeks.

For more resistant skin lesions, the product's effect may be enhanced by occlusion (e.g., polythene film), with overnight occlusion generally being adequate. If a dose is forgotten, it is applied as soon as remembered and then the usual schedule is resumed, but do not apply a double dose to compensate for the missed one. The treatment protocol explicitly avoids long-term continuous topical therapy.

Research evidence / Overview of studies for Stafine-cort

Evidence for Use in Inflammatory Dermatoses with Bacterial Involvement

The primary research base for combination products like Stafine-cort is derived from studies exploring conditions such as atopic, discoid, and stasis eczema where a bacterial component is confirmed or suspected. This evidence is relevant because the medicine includes both an anti-inflammatory agent and an antibiotic.

Research was evaluated in short-term clinical trials, typically lasting 7 to 14 days. These were often Randomized Controlled Trials (RCTs). Studies monitored patient-reported outcomes describing perceived discomfort and outcomes related to inflammatory or irritative states, such as changes in overall severity scores and the Investigator’s Global Assessment (IGA). Findings describe patterns observed in the combination groups, including measurements related to changes in severity scores and bacterial levels, compared to the groups receiving the non-active cream.

What Remains Uncertain in Primary Research

While research provides insight into short-term changes, long-term effects are not fully established beyond the initial treatment duration. Comparative evidence is sometimes lacking. For example, some systematic reviews have highlighted that research explored whether the antibiotic component provided an additional pattern of change compared to using the steroid alone when the eczema was not infected. Expert literature also describes concerns regarding the association between widespread topical antibiotic use and local antibiotic resistance, an area that continues to be monitored.

Evidence for Use in Other Steroid-Responsive Skin Conditions

Research has also explored the use of this combination in other conditions that respond to potent topical steroids, such as psoriasis and chronic lichen simplex. The evidence supporting the combination product in these settings is primarily drawn from extrapolation and is not based on a broad body of dedicated trials.

What Remains Uncertain in Secondary Research

Research has explored the specific contribution of the Fusidic Acid component for these conditions, and this remains somewhat uncertain. Because conditions like typical plaque psoriasis are not primarily characterized by a bacterial infection, comparative evidence is lacking from dedicated trials that specifically assess the patterns of change associated with the antibiotic component versus using the potent steroid alone in these cases.

Synthesis of Research Gaps and Uncertainty

The overarching evidence landscape highlights what is known—and what is still uncertain. Follow-up durations were limited in the pivotal efficacy trials, restricting the insight into long-term symptom patterns or chronic management. Furthermore, evidence is limited regarding the patterns of change associated with the combination product over a steroid-only cream when a bacterial infection has not been confirmed. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Key Studies & References

1. An Efficient New Formulation of Fusidic Acid and Betamethasone 17-Valerate (Fucicort Lipid Cream) for Treatment of Clinically Infected Atopic Dermatitis
2. Health Products Regulatory Authority Public Assessment Report for Fusidic acid/Betamethasone Bailleul Cream

Common questions about Stafine-cort (FAQ)

Q: What is the main difference between Stafine-cort and a regular antibiotic cream?

A: The main difference is the composition. A regular antibiotic cream typically contains only an antibacterial agent. Stafine-cort is a fixed-dose combination product containing both an antibacterial agent (Fusidic Acid) and a potent anti-inflammatory corticosteroid (Betamethasone).

Q: Is Stafine-cort the same as Fucidin H?

A: They are not the same medicine. While both are combination products containing the antibiotic Fusidic Acid, Stafine-cort contains the more potent corticosteroid Betamethasone. The similar product Fucidin H, by comparison, contains the less potent steroid Hydrocortisone. The difference lies in the specific steroid component used in the formulation.

Q: How long does it usually take to see results after starting Stafine-cort?

A: Official regulatory documents do not specify a precise time for the onset of results. However, they recommend that use should be stopped if there is no improvement in the skin condition after a short, set period, such as seven days. Regulatory guidance on treatment duration suggests that initial changes may be observed within the first week of use.

Q: Do you get withdrawal symptoms when stopping Stafine-cort?

A: Regulatory warnings state that potent topical steroids carry a risk of systemic absorption, especially when used for prolonged periods or over large areas. Due to this risk, the treatment duration is strictly limited to minimize the chance of HPA axis suppression, which may be linked to withdrawal-like symptoms if the medicine is discontinued following prolonged or extensive use.

Q: Can Stafine-cort make my skin thinner?

A: Official warnings describe that the potent corticosteroid component is associated with a risk of skin atrophy (thinning) and stretch marks. This risk is greater when the medicine is used for prolonged periods, under occlusion (bandages), or on sensitive areas like the face.

Q: Why is Stafine-cort sometimes only available by prescription?

A: The medicine is classified as a prescription-only product because it contains Betamethasone, which is categorized as a potent corticosteroid. Regulatory bodies require medical supervision for potent steroids due to the potential for serious side effects, such as HPA axis suppression, if used improperly.

Q: Is Stafine-cort okay to use on the face?

A: Official patient information advises avoiding use on the face due to the risk of developing skin atrophy (thinning) and other permanent changes, such as perioral dermatitis. Regulatory documents indicate that use on the face is permitted only under the direct supervision and instruction of a healthcare professional.

Q: Can Stafine-cort be used on sensitive areas of the body?

A: Regulatory warnings note that use in skin folds or intertriginous areas (such as the armpits or groin) may increase the risk of systemic absorption of the steroid component and other side effects. Application in these sensitive areas is generally limited to short durations under close medical supervision.

Q: Can Stafine-cort affect liver function?

A: The Betamethasone component of this medicine is metabolized (processed) primarily in the liver. Although the amount absorbed into the body is minimal with correct topical use, regulatory documents describe that caution may be necessary when the medicine is used by patients with impaired liver function.

Q: How is Stafine-cort different from other topical combination medicines?

A: The key differentiator is its unique formulation which combines the antibiotic Fusidic Acid with the potent steroid Betamethasone. Regulatory approval is based on the specific efficacy profile of this fixed-dose pairing, which is distinct from combination creams that use different steroids or antibiotics.

Q: Are there different strengths of Stafine-cort available?

A: Stafine-cort is officially designated as a fixed-dose combination product. Regulatory documents specify the standard concentration ratio—for example, 1, mg/g of Betamethasone and 20, mg/g of Fusidic Acid—in its various forms like cream or ointment.

Q: Does the application area need to be dry before using Stafine-cort?

A: Official patient information for topical treatments, including Stafine-cort, generally instructs that the affected skin area should be cleaned and dried carefully before a thin layer of the medicine is applied.

Q: Is it true that Stafine-cort can affect blood sugar levels?

A: The potent corticosteroid component (Betamethasone) is known to potentially interfere with blood sugar control, particularly if significant amounts are absorbed systemically. Regulatory warnings indicate that caution may be necessary when using the product in patients who have diabetes.

Q: Is Stafine-cort known to cause discoloration of the skin?

A: Potential skin changes, including discoloration (changes in skin color), are officially listed as a possible side effect of the corticosteroid component. This is often described as hypopigmentation, which is a lightening of the skin in the treated area.

Q: Can Stafine-cort be used alongside non-medicated moisturizers?

A: Regulatory guidance generally advises avoiding the application of other skin care products, including non-medicated moisturizers, to the treated area unless advised otherwise by a healthcare professional.

Q: How do I know if the infection requires Stafine-cort?

A: Official indications state the medicine is for use in inflammatory skin conditions only where a bacterial infection is present or highly likely, and the bacteria must be sensitive to the antibiotic component, Fusidic Acid. The prescription is based on this dual requirement.

Q: Why do doctors prescribe Stafine-cort instead of two separate creams?

A: Official guidance on fixed-dose combination products indicates they are prescribed when the combination offers a clear therapeutic or patient convenience advantage over using two separate products. This ensures both the inflammation and the bacterial component are addressed simultaneously.

Q: What is the function of the Hydrocortisone part of Stafine-cort?

A: This medicine does not contain Hydrocortisone. The steroid component is Betamethasone, which is classified as a high-potency corticosteroid. Its function is to reduce the inflammation, redness, and itching associated with the skin condition.

Q: Is Stafine-cort effective against all types of skin bacteria?

A: No, the antibiotic component, Fusidic Acid, is not effective against all types of bacteria. Official documents state that it is primarily effective against specific susceptible bacteria, mainly Gram-positive organisms such as Staphylococcus aureus.

Q: What is the difference between Stafine-cort cream and ointment?

A: Regulatory information notes that the components are provided in different forms, such as a cream and an ointment. Generally, topical ointments are considered to be slightly more potent than creams and are typically recommended for drier, scaly, or thickened patches of skin.

Q: Is Stafine-cort tested on animals?

A: Official regulatory documents, under the preclinical safety data sections, confirm that studies were conducted on animals for the individual active components. For instance, animal studies were used to assess potential reproductive toxicity associated with the corticosteroid component.

Q: Does Stafine-cort treat the cause of the skin problem or just the symptoms?

A: Stafine-cort is a combination product designed for dual action. It contains an antibiotic to target the bacterial infection (addressing a cause) and a potent corticosteroid to reduce inflammation, swelling, and itching (addressing symptoms). Official documents state its use is for inflammatory conditions where a bacterial component is present or likely.

Q: What are the most common side effects of Stafine-cort mentioned online?

A: Regulatory information classifies observed side effects by frequency. The reactions reported as 'uncommon' (meaning they affect up to 1 in 100 people) include minor issues like a slight burning or stinging sensation, irritation, or itching at the site of application.

Q: What should I do if Stafine-cort gets into my eyes?

A: Due to the potent steroid component, official warnings advise avoiding application near the eyes entirely, as there is a risk of developing conditions like increased intraocular pressure. If accidental exposure occurs, the patient information suggests rinsing the affected eye thoroughly with water.

Q: Can Stafine-cort be used for rashes that aren't infected?

A: According to the official product information, this combination medicine is intended specifically for inflammatory skin conditions only where a bacterial infection is present or suspected. Using the antibiotic component when it is not needed may contribute to the risk of developing antibiotic resistance.

Q: Are there specific instructions for stopping Stafine-cort application?

A: The most important instruction for stopping application is the mandatory duration limit. Official documents state that the treatment course should not normally exceed two weeks, as this short duration helps minimize the risks of systemic side effects and antibiotic resistance.

Storage Requirements

Stafine-cort must be stored at room temperature, specifically not above 30 C (86 F), to maintain its stability. The product must not be refrigerated or frozen. To protect the contents from moisture and light, the medicine should be kept in its original container and the tube tightly closed.

Stability and Child Safety

Once the tube is first opened, the product has a limited in-use shelf-life and must be used or discarded after a period of 3 to 6 months, depending on the specific formulation. Stafine-cort, like all medicines, must be stored out of the sight and reach of children.

Disposal and Handling

Any unused or expired Stafine-cort must be disposed of in accordance with local requirements; it must not be disposed of in wastewater. A specific fire warning is noted: fabrics that have come into contact with the product and dried are more easily ignited.